WALTHAM, Mass., July 24, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that Mary Lynne Hedley, Ph.D., President and Co-Founder of TESARO, has been appointed to the role of Chief Operating Officer.
"Since the founding of TESARO in 2010, Mary Lynne has been instrumental in defining our Company strategy, establishing and advancing our pipeline, and building the key functions required of a fully integrated biopharmaceutical company," said Lonnie Moulder, CEO of TESARO. "As President and COO, Mary Lynne will continue to lead TESARO's R&D, clinical, medical, regulatory affairs and manufacturing functions as we prepare for commercialization."
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.
CONTACT: Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or email@example.com